ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Calcineurin"

  • 2021 American Transplant Congress

    Cyp3a5 Extensive Metabolizer Phenotype May be Associated with an Increase in Class 2 Donor Specific Antibodies and Antibody-Mediated Rejection

    S. Mirza1, N. Wilson2, J. Van Zyl2, P. Nguyen2, T. Sam2, S. Hall2, M. Askar2, R. Patel2

    1Texas Tech Univeristy Health Sciences Center Jerry H. Hodge School of Pharmacy, Dallas, TX, 2Baylor University Medical Center at Dallas, Dallas, TX

    *Purpose: Tacrolimus (TAC) metabolism is highly dependent on CYP3A5, yet there is limited data on the effect of CYP3A5 genetic polymorphisms in heart transplant recipients…
  • 2021 American Transplant Congress

    Managing the Significant Drug-Drug Interaction Between Tacrolimus and Letermovir in Solid Organ Transplant Recipients

    J. Hedvat, J. Choe, D. Salerno, J. Scheffert, D. Bley, A. Anamisis, T. Shertel, J. Lee, E. Liu, N. W. Lange

    NewYork-Presbyterian Hospital, New York, NY

    *Purpose: Letermovir does not appear to share cross-resistance with ganciclovir and is not associated with nephrotoxicity or myelosuppressive effects, making it an attractive option for…
  • 2021 American Transplant Congress

    Relationship Between Tacrolimus Blood Levels and Covid-19 Pandemic in Kidney Transplant Recipients

    T. Inoue1, K. Unagami,2, A. Ishiwatari3, T. Kanzawa3, T. Shimizu3, K. Omoto3, M. Inui3, T. Suzuki1, H. Ishida4, K. Tanabe3

    1Department of Nephrology, Kameda Medical Center, Chiba Kamogawa, Japan, 2Department of Organ Transplant Medicine, Tokyo Women’s Medical University, Tokyo, Japan, 3Department of Urology, Tokyo Women’s Medical University, Tokyo, Japan, 4Department of Organ transplant medicine, Tokyo Women’s Medical University, Tokyo, Japan

    *Purpose: The novel coronavirus 2019 infection (COVID-19) caused a pandemic, prompting Tokyo, Japan, to restrict on the free movement of people in March 2020. Kidney…
  • 2021 American Transplant Congress

    A Comparison of Belatacept Conversion Regimens from Calcineurin Inhibitor-Based Immunosuppression

    E. Huang, A. Vo, A. Peng, R. Najjar, S. Sethi, S. Jordan

    Cedars-Sinai Medical Center, Los Angeles, CA

    *Purpose: Outcomes with varying belatacept conversion protocols from calcineurin inhibitor (CNI)-based immunosuppression have been published but no standard protocol has been established. Beginning in 2012,…
  • 2021 American Transplant Congress

    Higher Calcineurin Inhibitor Levels Associate with Graft Outcomes in Kidney Recipients with De Novo Donor-specific Antibodies of Either Hla Class I or II

    M. Béland, S. De Serres

    Nephrology, CHU de Québec- Université Laval, Québec, QC, Canada

    *Purpose: The development of de novo anti-HLA donor specific antibodies (dnDSA) is associated with poorer outcomes in kidney transplant recipients. We and other previously reported…
  • 2021 American Transplant Congress

    Evaluation of the Conversion from Tacrolimus to Sirolimus in Liver Transplant Recipients

    H. Bakhtiari1, S. Todd2, H. Snyder2, D. Lo2, M. Flynn2

    1Mercer University College of Pharmacy, Atlanta, GA, 2Emory University Hospital, Atlanta, GA

    *Purpose: The purpose of this study was to compare outcomes in liver transplant patients maintained on standard calcineurin inhibitor (CNI) therapy with tacrolimus versus those…
  • 2021 American Transplant Congress

    Early Reduction of Tacrolimus Trough Levels Improves Long-term Kidney Function without Increase in Incidence of Acr

    M. Chen1, B. Loza1, A. Chang1, R. Byfield2, K. Olthoff1, A. Shaked1

    1Department of Surgery, University of Pennsylvania, Philadelphia, PA, 2Data Analytics Center, Penn Medicine Information Systems, University of Pennsylvania Health System, Philadelphia, PA

    *Purpose: We examined the impact of clinical practice management of tacrolimus trough levels in liver transplant recipients on kidney function and incidence of rejection in…
  • 2020 American Transplant Congress

    Delayed Introduction of Mammalian Inhibitors of Rapamycin (mTOR) Post Kidney Transplantation Might Avoid the Chronic Nephrotoxicity of Calcineurin Inhibitors. Herein We Are Reporting an Eight-Years Single Center Experience of mTOR-Based Immunosuppression Regimen in Comparison with Cyclosporin-Based Regimen

    W. A. Hassan1, H. M. Tawfik2

    1Medicine-Nephrology, University of Tennessee Health Science Center, Memphis, TN, 2Medicine-Nephrology, Minia Nephrology Hospital, Minia University, Minia, Egypt

    *Purpose: Delayed introduction of mTOR inhibitors post kidney transplantation might avoid the chronic nephrotoxicity of CNI: eight-years single center experience.*Methods: This is a retrospective analysis…
  • 2020 American Transplant Congress

    Clinical Study of Standard versus Reduced Dose Tacrolimus Combined with Generic Mycophenolate Mofetil in De Novo Kidney Transplantation

    J. Bang, C. Oh

    Department of Surgery, Ajou University Medical School, Suwon, Korea, Republic of

    *Purpose: The lowering of calcineurin inhibitor exposure is possibly considered as the proper strategy to prevent calcineurin inhibitor induced nephrotoxicity in kidney transplant. This clinical…
  • 2020 American Transplant Congress

    Prospective, Randomized Study of Conversion from Calcineurin Inhibitor (CNI)- to Belatacept (BELA)-Based Maintenance Immunosuppression in Renal Transplant Recipients

    K. Budde1, R. Prashar2, H. Haller3, M. Rial4, N. Kamar5, A. Agarwal6, J. de Fijter7, L. Rostaing8, S. Berger9, A. Djamali10, N. Leca11, L. Allamassey12, S. Gao12, M. Polinsky12, F. Vincenti13

    1Charité Universitätsmedizin Berlin, Berlin, Germany, 2Henry Ford Hospital, Detroit, MI, 3The Hannover Medical School, Hannover, Germany, 4Instituto de Nefrologia, Nephrology SA, Buenos Aires, Argentina, 5University of Toulouse, Toulouse, France, 6UVA Health, Charlottesville, VA, 7Leiden University Medical Center, Leiden, Netherlands, 8Université Grenoble Alpes, Saint-Martin-d'Hères, France, 9University Medical Centre Groningen, Groningen, Netherlands, 10University of Wisconsin, Madison, WI, 11UW Medical Center, Seattle, WA, 12Bristol-Myers Squibb, Princeton, NJ, 13University of California, San Francisco, San Francisco, CA

    *Purpose: CNIs are associated with adverse systemic and nephrotoxic effects that negatively impact long-term patient and graft survival. In a phase 2 study, switching renal…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 16
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences